INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer

[1]  B. Parvin,et al.  Overexpression of CD36 in mammary fibroblasts suppresses colony growth in breast cancer cell lines. , 2020, Biochemical and biophysical research communications.

[2]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[3]  G. Mariani,et al.  Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. , 2019, Critical reviews in oncology/hematology.

[4]  S. Thiagalingam,et al.  Activin A Signaling Regulates IL13Rα2 Expression to Promote Breast Cancer Metastasis , 2019, Front. Oncol..

[5]  H. Iwata,et al.  Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03 , 2018, Breast cancer research and treatment.

[6]  A. Larionov.  Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients , 2018, Front. Oncol..

[7]  Joe W. Gray,et al.  Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes , 2018, Cell systems.

[8]  Publisher's Note , 2018, Anaesthesia.

[9]  H. Riezman,et al.  Detection of genome-edited mutant clones by a simple competition-based PCR method , 2017, PloS one.

[10]  Jennifer M. Carr,et al.  Intrinsic Subtype and Therapeutic Response Among HER2‐Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial , 2017, Journal of the National Cancer Institute.

[11]  Maria Namwanje,et al.  Activins and Inhibins: Roles in Development, Physiology, and Disease. , 2016, Cold Spring Harbor perspectives in biology.

[12]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[13]  W. Berger,et al.  High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma , 2016, Oncotarget.

[14]  J. Gray,et al.  Therapeutic siRNA for drug-resistant HER2-positive breast cancer , 2016, Oncotarget.

[15]  Mohsin Bashir,et al.  Activin-A signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancer , 2015, npj Breast Cancer.

[16]  Laura M. Heiser,et al.  Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer , 2015, PloS one.

[17]  S. Paik,et al.  Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Chien-Feng Li,et al.  INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract , 2015, Journal of surgical oncology.

[19]  C. Andl,et al.  Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion , 2014, Cancers.

[20]  Sung-Bae Kim,et al.  Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Winer,et al.  Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[23]  Laura M. Heiser,et al.  Modeling precision treatment of breast cancer , 2013, Genome Biology.

[24]  Sumin Zhao,et al.  An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models , 2013, Breast Cancer Research.

[25]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[26]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[27]  Johan Staaf,et al.  GOBO: Gene Expression-Based Outcome for Breast Cancer Online , 2011, PloS one.

[28]  Yan Sun,et al.  Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[30]  B. Druker,et al.  RNAi screen for rapid therapeutic target identification in leukemia patients , 2009, Proceedings of the National Academy of Sciences.

[31]  D. Beer,et al.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. , 2009, Neoplasia.

[32]  F. Meng,et al.  Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. , 2008, Human pathology.

[33]  Genee Y. Lee,et al.  Three-dimensional culture models of normal and malignant breast epithelial cells , 2007, Nature Methods.

[34]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[35]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[36]  G K Smyth,et al.  Leishmaniasis host response loci (lmr1–3) modify disease severity through a Th1/Th2-independent pathway , 2004, Genes and Immunity.

[37]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  N. Ling,et al.  FOLLISTATIN BINDS TO BOTH ACTIVIN AND INHIBIN THROUGH THE COMMON BETA-SUBUNIT , 1991 .

[39]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[40]  N. Ling,et al.  Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[42]  C. Andl,et al.  Activin receptor-like kinases: a diverse family playing an important role in cancer. , 2016, American journal of cancer research.

[43]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[44]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[45]  N. Ling,et al.  Follistatin binds to both activin and inhibin through the common subunit. , 1991, Endocrinology.